Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Constrictive Bronchiolitis Clear all
Completed Phase 2 Interventional

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

NCT02649218
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 22, 2026, 7:32 AM EDT
Recruiting Not applicable Interventional

Freedom-1 Study for Chronic Knee Pain

NCT03877653
View directory record Official record
Conditions
Osteoarthritic Knee Pain
Interventions
Wireless neuromodulation
Device
Lead sponsor
Curonix LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Placentia, California • Denver, Colorado • Fort Lauderdale, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 22, 2026, 7:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil, Placebo, Prednisone, Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
24
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 22, 2026, 7:32 AM EDT
Completed No phase listed Observational

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

NCT05669677
View directory record Official record
Conditions
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD, NASH
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

NCT02959944
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ibrutinib, Placebo, Prednisone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
12 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 22, 2026, 7:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

tDCS as an Adjuvant to Intensive Speech Therapy for Chronic Post Stroke Aphasia

NCT02801864
View directory record Official record
Conditions
Aphasia, Language
Interventions
Real tDCS, Sham tDCS, Intensive Speech Therapy
Device · Other
Lead sponsor
Austin Speech Labs
Other
Eligibility
20 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 22, 2026, 7:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT03584516
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Itacitinib, Placebo, Methylprednisolone, Prednisone
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

NCT02013427
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Placebo, Omeprazole
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Early Phase 1 Interventional Results available

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

NCT01380535
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ECP Methoxsalen, Standard of Care
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 22, 2026, 7:32 AM EDT
Terminated Phase 2 Interventional Results available

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

NCT02337517
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Laboratory Biomarker Analysis, Vismodegib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 22, 2026, 7:32 AM EDT
Withdrawn Not applicable Interventional

Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial

NCT03696524
View directory record Official record
Conditions
Pleural Effusions, Chronic, Congestive Heart Failure, Shortness of Breath
Interventions
tunneled pleural catheter
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 22, 2026, 7:32 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Placebo, Corticosteroids
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed No phase listed Observational

Bion Occipital Nerve Stimulation (ONS) Compassionate Use Study

NCT01050959
View directory record Official record
Conditions
Chronic, Medically Refractory Headache
Interventions
bion
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Phoenix, Arizona • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 22, 2026, 7:32 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

AMPLIFI: Adaptive Modulation of Plasticity Through Lactate and Fitness Interventions

NCT06950060
View directory record Official record
Conditions
Stroke, Chronic, Aging, Cognitive Decline, Motor Dysfunction, Neuroplasticity
Interventions
High intensity cycling, Low-intensity cycling, Health education session, Moderate Intensity Aerobic Exercise
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Sofosbuvir, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)

NCT01161628
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Rituximab
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

NCT01650545
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions
Liposomal aerosol cyclosporine, standard immune suppression, oral
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Not applicable Interventional Results available

Improving Chronic Disease Management With Pieces

NCT02587936
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes
Interventions
Collaborative Model of Primary care and Subspecialty care
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
18,268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Farmington, Connecticut • Arlington, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 22, 2026, 7:32 AM EDT
Recruiting Not applicable Interventional

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

NCT05236062
View directory record Official record
Conditions
Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Interventions
Exercise, Attention control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Completed No phase listed Observational

Review of Infant Oral Feeding and Skills

NCT06736743
View directory record Official record
Conditions
Nutrition Disorders, Gastrointestinal Disease, Deglutition Disorder, Feeding Difficulties, Swallowing Difficulties, Humans, Cohort Studies, Infant, Newborn, Infant, Premature, Nutrition, Pediatric Feeding Disorder, Chronic, Retrospective Studies, Breastfeeding, Mental Health Wellness, Intensive Care Units, Neonatal, Bottle Feeding
Interventions
SMART Tool for Feeding Skill Assessment
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
22 Weeks to 42 Weeks
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 22, 2026, 7:32 AM EDT
Suspended Phase 1 Interventional

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT05993611
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
Interventions
Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Echocardiography, Electronic Health Record Review, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Quality-of-Life Assessment, Tafasitamab, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 22, 2026, 7:32 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

NCT02701634
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ENTO, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 22, 2026, 7:32 AM EDT
Completed Phase 3 Interventional

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

NCT00268957
View directory record Official record
Conditions
Kidney Diseases, Chronic Renal Insufficiency, End-Stage Renal Disease
Interventions
Sevelamer carbonate (Renvela®), Sevelamer hydrochloride (Renagel®)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
29
States / cities
Birmingham, Alabama • Gadsden, Alabama • Mission Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 22, 2026, 7:32 AM EDT